Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jim X Xiang

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Journal of Biopharmaceutical Statistics|January 29, 2015
On two-sample McNemar testJim X Xiang
Clinical Therapeutics|October 4, 2005
A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumoniaAndrew F Shorr, Neringa Zadeikis, Jim X Xiang, et al.
Respiratory Medicine|May 30, 2006
Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patientsAndrew F Shorr, Mohammed M Khashab, Jim X Xiang, et al.
Current Medical Research and Opinion|September 24, 2004
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumoniaThomas M File, Gary Milkovich, Alan M Tennenberg, et al.
Current Medical Research and Opinion|May 4, 2004
Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogensLala M Dunbar, Mohammed M Khashab, James B Kahn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigmLala M Dunbar, Richard G Wunderink, Michael P Habib, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Journal of Biopharmaceutical Statistics|January 29, 2015
On two-sample McNemar testJim X Xiang
Clinical Therapeutics|October 4, 2005
A multicenter, randomized, double-blind, retrospective comparison of 5- and 10-day regimens of levofloxacin in a subgroup of patients aged > or =65 years with community-acquired pneumoniaAndrew F Shorr, Neringa Zadeikis, Jim X Xiang, et al.
Respiratory Medicine|May 30, 2006
Levofloxacin 750-mg for 5 days for the treatment of hospitalized Fine Risk Class III/IV community-acquired pneumonia patientsAndrew F Shorr, Mohammed M Khashab, Jim X Xiang, et al.
Current Medical Research and Opinion|September 24, 2004
Clinical implications of 750 mg, 5-day levofloxacin for the treatment of community-acquired pneumoniaThomas M File, Gary Milkovich, Alan M Tennenberg, et al.
Current Medical Research and Opinion|May 4, 2004
Efficacy of 750-mg, 5-day levofloxacin in the treatment of community-acquired pneumonia caused by atypical pathogensLala M Dunbar, Mohammed M Khashab, James B Kahn, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 5, 2003
High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigmLala M Dunbar, Richard G Wunderink, Michael P Habib, et al.
Pageof 1